EP1830787A1 - Association of vegetal extracts based on gooseberries, black orchids and black tulips and topical composition comprising the association of said vegetal extracts - Google Patents

Association of vegetal extracts based on gooseberries, black orchids and black tulips and topical composition comprising the association of said vegetal extracts

Info

Publication number
EP1830787A1
EP1830787A1 EP05775497A EP05775497A EP1830787A1 EP 1830787 A1 EP1830787 A1 EP 1830787A1 EP 05775497 A EP05775497 A EP 05775497A EP 05775497 A EP05775497 A EP 05775497A EP 1830787 A1 EP1830787 A1 EP 1830787A1
Authority
EP
European Patent Office
Prior art keywords
association
black
skin
topical composition
aging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05775497A
Other languages
German (de)
French (fr)
Inventor
Jacques Leclere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MESYL LIMITED
Original Assignee
De Gunzburg Terry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Gunzburg Terry filed Critical De Gunzburg Terry
Publication of EP1830787A1 publication Critical patent/EP1830787A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • the present invention relates to an association based plant extracts of gooseberry, black orchid and black tulip, and a topical composition containing it, and more particularly a composition containing such an association, useful for the treatment and the prevention of damage related to the aging of the skin, as well as the associated cosmetic processes.
  • the skin has several integrated layers, ranging from the superficial layer, the epidermis, to the deeper layers, the dermis and the hypodermis, and each has specific properties allowing the whole to react and adapt to conditions of its environment.
  • the epidermis is mainly composed of three types of cells which are keratinocytes (90% of epidermal cells), melanocytes (2 to 3% of epidermal cells) and Langerhans cells.
  • the epidermis which constitutes the outer layer, plays a fundamental role in ensuring the protection and maintenance of good trophicity. This is why many compositions have been developed to protect and improve its functions, including strengthening its elasticity and firmness.
  • the dermis is thick, solid, rich in nerves and blood vessels and sweat glands. It protects and repairs damaged tissues. This layer consists mainly of collagen, elastin and proteoglycans. These three types of molecules are synthesized by dermal fibroblasts. Collagen fibers, which represent 70% of the dry weight of the dermis, form a support network responsible for the mechanical characteristics of the skin such as strength and texture.
  • Elastin is responsible for elasticity and proteoglycans play a major role in structure and hydration of the skin.
  • Other cells such as macrophages and leucocytes are also present in the dermis layer.
  • the hypodermis attached to the bottom of the dermis, is the deepest layer of the skin. It contains lipid-producing fat cells to produce a fat layer that protects the muscles, bones, and internal organs from shock, and acts as an insulator and energy source during periods of time. young.
  • One of the first signs of skin aging is a loss of elasticity and the formation of fine lines and wrinkles, which are a direct result of the deterioration of the dermis layer of support.
  • the ability of the skin to replace damaged collagen decreases and more spaces and irregularities develop in the collagen network.
  • the appearance of pigment marks, the fineness of the skin and the sagging of the skin are also changes observed during the subsequent aging of the skin.
  • Many factors contribute to accelerating the breakdown of collagen particularly sun exposure, free radicals, certain hormonal changes associated with old age, and tobacco.
  • the aging of the skin is often described as appearing in two ways. The first is chronological or intrinsic aging, while the second is extrinsic aging, namely aging caused by the environment; this is particularly the case of photoaging, which is the damage done to the skin because of the direct or indirect effects of ultraviolet light.
  • the present invention relates not only to intrinsic aging, but also to extrinsic aging.
  • aging causes in particular a decrease in protein synthesis (collagen, elastin) a decrease in the synthesis of proteoglycans among others, as well as an elevation of metalloproteinases of MMP3 type.
  • oxidation phenomena free radical content
  • Collagen implants have also been proposed to conceal expression lines around the eyes or mouth, dermabrasion and chemical peels to remove the upper layer of damaged skin, cosmetic surgery, such as blepharoplasty (surgical procedures).
  • Patent application WO 02069992 lists a large number of plant extracts obtained under particular conditions where the plant is previously subjected to stress, and likely to provide an inhibitory effect of certain extracellular proteases and consequently to limit the effects harmful to these proteases.
  • the use of certain plant extracts in cosmetic compositions is also described in patent applications JP 02279618 relating to water-soluble extracts of orchid with moisturizing action, JP 2003040758 relating to extracts of saxifrage and JP 10007582 relating to extracts of tulip.
  • the subject of the present invention is therefore an association of vegetable extracts based on gooseberry, black orchid and black tulip.
  • the present invention also relates to a topical composition for the treatment or prevention of damage related to aging of the skin, comprising an association according to the first subject of the invention indicated above.
  • the invention also aims to propose the use of an association as above, for the preparation of a topical composition for combating skin aging damage.
  • the subject of the present invention is also a cosmetic process for combating skin aging damage, which comprises the step of applying to a region of the affected skin a composition containing an effective amount of the topical composition according to the second object of the present invention.
  • the cosmetic process for improving the external appearance comprising a step of applying this topical composition to the areas of the affected skin is also another object of the present invention.
  • These topical compositions can advantageously be used in dermatology or cosmetology for the treatment or prevention of damage associated with aging of the skin, more particularly including the loss of skin firmness and tone, and the appearance of wrinkles. and fine lines.
  • the topical composition is useful for dermatological or cosmetic purposes, unless otherwise indicated.
  • the gooseberry is particularly known for its high content of polyphenols (RIBES UVA CRISPA).
  • the gooseberry in Maquereau originates from Asia and has become sub-spontaneous in Northern and Eastern Europe. It is found in plain or low mountain colonizing poor environments or even specifically acidic terrains. For example it is found in the Vosges up to 1000 m altitude and on the banks of the Loire in flood zone. It is the fruit that is used.
  • the Black Orchid Cycnoches Cooperi
  • like all orchids lives in poor conditions and pine bark or debris of lichen may be sufficient for its development.
  • the Black Orchid is particularly rich in flavonoids which have a particular interest as scavengers of free radicals and protectors meinbranaires. It is the whole plant that is used.
  • the Black Tulip (Tulipa Nigra) is the plant that contains the most plant DNA. It is a cultivated tulip. Its origin in the mountainous regions of northern Europe and Asia explains its great qualities of resistance and repro ⁇ duction, as well as a great resistance to UV. It is an extract of the petals that is used. These plant extracts can be characterized by their dry extract content and / or by their active content.
  • the extracts are advantageously hydro-glycol or hydro-alcoholic extracts, for example obtained by cold maceration in a water / propylene glycol or water / ethanol mixture.
  • the extracts detailed below may be used for the preparation of the combination according to the present invention.
  • the combination may also take the form of oily extracts that can be obtained by macerating the plants in capric triglycerides / caprylic, oleic sunflower or any polar / apolar mixture of the type of apricot kernel oil / Vaseline oil. It is thus possible to extract liposoluble materials such as flavones and certain polyphenols.
  • the topical compositions according to the invention may be in any cosmetic formulation.
  • the topical compositions according to the invention may for example comprise excipients suitable for external topical administration, in particular excipients dermatologically acceptable.
  • excipients suitable for the formulation include in particular thickeners such as natural gums and synthetic polymers; emollients and surfactants such as cetearyl octanoate, isopropyl myristate, cetearyl isononanoate, dimethicone, cyclomethicone, polyglyceryl 3-diisostearate, hydrogenated polyisobutene, cetyl alcohol cetyl palmitate, cetyl phosphate; emulsifiers; preservatives such as phenoxyethanol, methyl parahydroxybenzoate (methyl paraben), propylparaben parahydroxybenzoate and Phenonip® associating phenoxyethanol and methyl, ethyl, butyl and isobutyl parahydroxybenzoates; dyes; the perfumes ; etc.
  • thickeners such as natural gums and synthetic polymers
  • emollients and surfactants such as cetearyl octanoate, iso
  • compositions may be used in the compositions: moisturizing agents such as propylene glycol, glycerol, butylene glycol and also antioxidant vitamins such as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols.
  • Skin conditioning agents such as nylon can also be added to the composition.
  • the topical compositions according to the invention may be in the form of a solution, a hydrophilic lotion, an ointment, a cream, a serum or a gel.
  • the compositions may also be, for example, in the form of oil-in-water, water-in-oil or multiple emulsions, foaming products or in the form of liposomes.
  • each of the vegetable extracts of gooseberry, black orchid and black tulip is advantageously present in a content of between 5 and 90%, these contents being expressed relative to total weight of the association.
  • these contents are approximately 25 to 50%, and more preferably an association comprising the three extracts in substantially equal amounts is used.
  • the topical compositions according to the invention typically comprise between 0.1% and 20% (w / w) by weight of the combination according to the present invention relative to the total weight of the topical composition, and preferably from 2% to 8% by weight. %.
  • the extracts constituting the combination of the invention are supplemented with active ingredients or auxiliary ingredients chosen for their complementary properties, in order to reinforce the anti-aging effects of the composition.
  • Imperata cylindrica for example MOIST 24® from Sederma
  • an antihyaluronidase such as Echinacin B in order to generate a maximum of bound water, of Imperata cylindrica, for example MOIST 24® from Sederma
  • amaranth seed protein Amarantus caudatus
  • pea globulins to obtain a skin tightening effect
  • Calophylum oil to enhance the effect anti-wrinkles
  • Echium oil for its anti-inflammatory effect or palmitoyl pentapeptide-3
  • Matrixyl® or derivatives such as palmitoyl GHK (having the glycyl-Histidyl-Lysine chain) and the palmitoyl GQPR (Glycyl-Glutamyl-Prolyl-Arginine) or palmitoyl VGVAPG (Valyl-Glycyl-Valyl-
  • the topical compositions according to the invention have an effect of improving cutaneous damage due to aging.
  • the first results can be obtained after 2 to 3 weeks of daily treatment by applying the compositions once or twice a day to the areas of the skin to be treated.
  • Said compositions of the invention may be chosen for day and / or night use on the face, body and hands.
  • the compositions according to the invention are particularly suitable for the treatment of the contour areas of the eyes and lips, which are very fragile and highly susceptible to the appearance of wrinkles and loss of firmness of the skin.
  • the compositions according to the invention are very well tolerated on this sensitive area, and make possible a visible reduction in the number of wrinkles and marks on the eyes, as well as a particularly sensitive skin firming of the eye and mouth contours.
  • Example 5 relates to a toxicological study and to tests of activity on human fibroblasts, which made it possible to evaluate the anti-inflammatory effect (interleukins) and the anti-aging effect (MPP3 assay, proteoglycans and collagens).
  • the "plant complex” corresponds to an association based on vegetable extracts of gooseberry, black orchid and black tulip according to the present invention in which the three extracts are those detailed. above (extracted by cold maceration of a mixture of water / propylene glycol or water / ethanol) and they are included in equal parts. Unless otherwise indicated, the compositions are given in parts by weight.
  • Example 4 Regenerating anti-wrinkle serum Mixture of lyophilized plants: - Polyphenols of Currant Mackerel 0.05 - Orchid Extract 0.10 - DNA of Black Tulip 0.20 - Glycocolin Q, 65 TOTAL 1.00 In lyophilized vial Solvent Glycerin 0, 5 - Butylene glycol 0.5 Biosaccharide grum-1 1.0 - Phenonip 0.07 - Pea Globulins 2.0 Imperata cylindrica extract 0.3 Amaranth Proteins 1.0 - Demineralized Water QSP 10.0 The lyophilized portion is dissolved by the solvent and provides a treatment for 7 days.
  • Example 5 In addition to the toxicology of the product, studies on human fibroblasts in culture were conducted.
  • fibroblasts in culture The fibroblast cultures are established from human foreskin skin harvested during circumcisions and are amplified in RPMI 1640 culture medium supplemented with fetal calf serum, L-glutamine and gentamycin. The fibroblasts were seeded in boxes of 25 cm 2 at a rate of 10 ⁇ cells per ml. They were then incubated for 24 hours.
  • Toxicological aspect The purpose of this first step was to seek the cytotoxicity of the product with respect to human fibroblasts in culture. The cell growth is carried out on 3 non-cytotoxic concentrations. Cytotoxicity was achieved by determining neosynthesis of proteins.
  • Human fibroblasts obtained by primoculture were recovered after trypsinization and centrifugation.
  • the cell pellet was resuspended in 10 ml of RPMI 1640 medium supplemented with fetal calf serum (10%), L-glutamine (8 mM) and gentamicin (80 ⁇ g / ml).
  • the cells were distributed in multiwell plates (6 wells) at a rate of 1.10 5 cells / ml. The plates were incubated for 24 hours. The medium was then removed and fresh medium was added either alone or supplemented with different concentrations of the "plant complex" product 0.1%, 0.2%, 0.5%, 1% and 5%). The contact times of the product with the cells were 24 hours.
  • Radioactive precursors were added to the cultures after the incubation times with the product at different concentrations.
  • the cells were then incubated for an additional two hours at 37 ° C. in the presence of 3 H-leucine (1 ⁇ Ci / ml of culture medium, specific activity: 5 Ci / mmol).
  • 3 H-leucine (1 ⁇ Ci / ml of culture medium, specific activity: 5 Ci / mmol).
  • the cells were washed twice with serum-free medium to remove unincorporated radioactivity and then detached from the support by scratching the culture surface.
  • the cells were washed again and then centrifuged at 600 g for 5 minutes.
  • the cell pellet was taken up in 500 ⁇ l of medium.
  • radioactivity For the determination of the radioactivity incorporated into the macromolecules, 500 ⁇ l of 20% (w / v) NaOH were added, and then the whole was subjected to hydrolysis for 30 minutes at 37 ° C. The hydrolysates were then precipitated. with 1 ml of a 40% trichloroacetic acid (TCA) solution. The preparations are left for one hour at 40 ° C. The samples were filtered on a fiberglass filter (Whatman GF / A) mounted in Millipore apparatus. The filters were washed three times with 10 ml of 5% TCA and twice with 95% ethanol and then introduced into counting flasks and dried for 30 minutes at 80 ° C. The radioactivity was measured in a counter.
  • TCA trichloroacetic acid
  • fibroblasts were used in large numbers to have a sufficient amount of proteoglycans and glycosaminoglycans.
  • the fibroblasts were distributed in multiwell wells (6 wells) at a rate of 2.10 5 / ml in 3 ml of culture medium. They were then kept for 24 hours in CO 2 ovens.
  • the pulsation technique was adopted. The radioactive precursor ([3H] - Glucosamine) was added to the cultures 18 hours before cell recovery.
  • the contact time of the cells with the product was 24 hours at 37 ° C. After removing the medium by suction, the cells were washed twice with serum-free medium to eliminate the unincorporated radioactivity, and then detached from the support. by scratching the surface of the crop. The cells were washed again with medium and then recentrifuged at 600 g for 5 minutes. From this final pellet were made: - the proteoglycan assay by FPLC (Fast Protein Liquid Chromatography) - the neosynthesis of total glycosaminoglycans (GAGs) - the total protein assay
  • Perimembrane Proteoglycans A first fraction of the pellet was resuspended in 1M NaCl containing deoxyribonuclease (50 U / ml) and protease inhibitors. The homogenate was then incubated at 4 ° C for 2 hours. Centrifugation for 30 minutes at 12,000 g allowed to obtain the first homogenate containing peri-membrane proteoglycans. The pellet was used to extract the proteoglycans from the other 2 compartments (Cl).
  • Matrix proteoglycans The C2 pellet was washed three times with 0.1% sodium azide and then resuspended with stirring in a 50 mM sodium acetate buffer containing 4 M guanidine HCl and triton X-100 0, 1% as well as protease inhibitors. Centrifugation for 30 minutes at 12,000 g yielded the third supernatant containing the matrix proteoglycans.
  • each of the 3 supernatants was precipitated overnight at 40 ° C. in a volume of absolute ethanol and then centrifuged at 12,000 g for 30 minutes. The pellets obtained were resuspended in a 5mM Tris-HCl buffer pH 7.4. The same analysis protocol was performed for 3 solutes. Anion exchange chromatography was used. Each pellet was resuspended in 250 ml of 50 mM Tris-HCl buffer pH 7.4. Sepharose gel CL-6B (DEAE) (Pharmacia) was cast in a K 10/40 column (Pharamcia). The anion exchange gel has a high resolution and a good yield. 100 ⁇ l of each sample were injected; Elution is monitored by 280 nm wavelength spectrofluorometer detection. The peak containing the proteoglycans is eluted at 1 M NaCl. dosage
  • the radioactivity assay is performed at the HPLC outlet using a Packard meter (Flow-one).
  • fibroblasts were cultured in the same way as in section 1.4.1. After the incubation time, the fibroblasts are recovered by centrifugation. The pellets are digested with collagen (1 mg / cell pellet) in acetic acid 0.5 ml / 1 for 24 hours at 4 ° C. After centrifugation at 10,000 g, the collagens are precipitated by sodium chloride ( 1M NaCl), the precipitate is resuspended and then dialyzed. The primary amino acids are derived by ophthaldehyde acid (OPA) thus eliminating their interference.
  • OPA ophthaldehyde acid
  • NBD-Cl Hydroxyproline and proline are then derived by NBD-Cl by coupling of the amino groups to NBD-Cl.
  • the NBD-Hyp is separated and identified by reverse phase HPLC.
  • a coupling to the NBD-CL of a standard containing the hydroxyproline is first carried out.
  • - Hydroxyproline is measured by fluorescence measurement after reverse phase HPLC separation: o Automatic injector o Ultrasep C18 column (30cm * 0.18cm) o 6 ⁇ m porosity o Fluorescence detector
  • the mobile phase consists of a mixture of acetonitrile / 0.1 mol / l sodium phosphate buffer, pH 7.2 (9:91 v / v), the flow rate is set to 1 ml / min, the elution is carried out in static mode and the cycle is 10 minutes.
  • the mobile phase is filtered beforehand and degassed before use.
  • the standard range is prepared from a 50 mg / l hydroxyproline solution. Successive dilutions make it possible to obtain solutions ranging from 0.5 to 40 mg / l.
  • Derivatization and establishment of the calibration curve are performed from 10 .mu.l of a standard solution at different concentrations mixed with 10 .mu.l of the buffer.
  • the tubes After addition of 5 ⁇ l of OPA and stirring, the tubes are kept for 5 min at ambient temperature and then 10 ⁇ l of the NBD-Cl solution are added. The derivate is at 60 ° C in a water bath for 3 minutes, protected from light. The tubes are then removed and the orange color makes it possible to check the derivatization. They are then put in the ice to ensure cooling. 50 ⁇ l of this mixture are then injected into the column in order to obtain the calibration curve which must be linear. The samples are treated in the same way.
  • MMP-3 Metalloproteinase 3 Detection Kit

Abstract

The invention relates to an association of vegetal extracts which can be used in a topical composition. The association of vegetal extracts is based on gooseberries, black orchids and black tulips, the content thereof ranging from 5 to 90 % in relation to the total weight of the association. Application: treatment or prevention of damage to the skin associated with aging.

Description

ASSOCIATION D'EXTRAITSVEGETAUXABASE DE GROSEILLE MAQUEREAU, D'ORCHIDEE NOIRE ET DE TULIPE NOIRE ETCOMPOSITION TOPIQUE COMPRENANT L'ASSOCIATION DE CES EXTRAITSVEGETAUX ASSOCIATION OF EXTRACTSVEGETAUXABASE OF GROSEILLE MAQUEREAU, BLACK ORCHID AND BLACK TULIP AND TOPICAL COMPOUND COMPRISING THE ASSOCIATION OF THESE VEGETABLE EXTRACTS
La présente invention concerne une association à base d'extraits végétaux de Groseille à Maquereau, d'Orchidée Noire et de Tulipe Noire, ainsi qu'une composition topique la contenant, et plus particulièrement une composition contenant une telle association, utile pour le traitement et la prévention des dommages liés au vieillissement de la peau, ainsi que les procédés cosmétiques associés. La peau comprend plusieurs couches intégrées, allant de la couche superficielle, l'épiderme, jusqu'aux couches plus profondes, le derme et l'hypoderme, et chacune possède des propriétés spécifiques permettant à l'ensemble de réagir et de s'adapter aux conditions de son environnement. L'épiderme est principalement composé de trois types de cellules qui sont les kératinocytes (90% des cellules épider- miques), les mélanocytes (2 à 3% des cellules épidermiques) et les cellules de Langerhans. Son épaisseur varie selon les différentes parties du corps. L'épiderme, qui constitue la couche externe, joue un rôle fondamental pour assurer la protection et le maintien d'une bonne trophicité. C'est pourquoi de nombreuses compositions ont été mises au point afin de le protéger et d'améliorer ses fonctions, et notamment de renforcer son élasticité et sa fermeté. Le derme est épais, solide, riche en nerfs et en vaisseaux sanguins et en glandes sudoripares. Il protège et répare les tissus abîmés. Cette couche se compose princi¬ palement de collagène, d'élastine et de protéoglycanes. Ces trois types de molécules sont synthétisés par les fibroblastes dermiques. Les fibres de collagène, qui représentent 70% du poids sec du derme, forment un réseau de support responsable des caractéristiques mécaniques de la peau telles que la résistance mécanique et la texture. L'élastine est responsable de l'élasticité et les protéoglycanes jouent un rôle majeur de structure et d'hydratation de la peau. D'autres cellules comme les macrophages et les leucocytes sont également présentes dans la couche du derme. L'hypoderme, fixé au bas du derme, est la couche la plus profonde de la peau. Il contient les adipocytes qui produisent des lipides pour que le tissu sous-cutané fabrique une couche grasse qui protège les muscles, les os et les organes internes contre les chocs, et agit en tant qu'isolant et source d'énergie pendant les périodes de jeûne. L'un des premiers signes de vieillissement de la peau est une perte d'élasticité et la formation de rides et ridules, qui sont le résultat direct de la détérioration de la couche du derme de soutien. En fait, la capacité de la peau à remplacer le collagène endommagé diminue et il se développe plus d'espaces et d'irrégularités dans le réseau du collagène. L'apparition de marques pigmentaires, la finesse de la peau et l'affaissement de la peau sont également des changements observés au cours du vieillissement ultérieur de la peau. De nombreux facteurs contribuent à accélérer la dégra- dation du collagène, et en particulier l'exposition au soleil, les radicaux libres, certains changements hormonaux associés à la vieillesse, et le tabac. Le vieillissement de la peau est souvent décrit comme apparaissant de deux façons. La première est le vieillissement chronologique ou intrinsèque, tandis que la deuxième est le vieillissement extrinsèque, à savoir le vieillissement provoqué par l'environnement ; ceci est plus particulièrement le cas du photovieillissement, qui est cet endommagement fait à la peau du fait des effets directs ou indirects de la lumière ultra-violette. La présente invention a trait non seulement au vieillissement intrinsèque, mais également au vieillissement extrinsèque. A l'échelle de la peau, le vieillissement provoque notamment une diminution des synthèses protéiques (collagène, élastine) une diminution de la synthèse des protéoglycanes entre autres, ainsi qu'une élévation des métalloprotéinases de type MMP3. Par ailleurs, les phénomènes d'oxydation (teneur en radicaux libres) entraînent des processus inflammatoires qui augmentent la sensibilité cutanée. Pour lutter contre le vieillissement de la peau, on a proposé certains traitements à base de crèmes contenant des alpha-hydroxyacides ou des rétinoïdes, appliquées régulière¬ ment pour réduire à long terme le nombre des fines ridules. On a aussi proposé des implants de collagène pour dissimuler les lignes d'expression autour des yeux ou de la bouche, la dermabrasion et les peelings chimiques pour éliminer la couche supérieure de la peau endommagée, la chirurgie esthétique, telle que la blépharoplastie (chirurgie des paupières) ou un lifting pour rajeunir une peau s 'affaissant, ou encore une restructuration à l'aide d'un laser au dioxyde de carbone pour éliminer les ridules et améliorer les cicatrices. La demande de brevet WO 02069992 cite un grand nombre d'extraits de plantes obtenus dans des conditions particu- lières où la plante est préalablement soumise à un stress, et susceptibles de procurer un effet inhibiteur de certaines protéases extracellulaires et par conséquent de limiter les effets néfastes attribués à ces protéases. L'utilisation de certains extraits de plantes dans des compositions cosmétiques est aussi décrite dans les demandes de brevet JP 02279618 relative à des extraits hydrosolubles d'orchidée à action hydratante, JP 2003040758 relative à des extraits de saxifrage et JP 10007582 relative à des extraits de tulipe. Cependant, il existe toujours un besoin accru de trouver des compositions topiques alternatives permettant de lutter efficacement contre le vieillissement cutané, et notamment de trouver des compositions topiques à base d'extraits végétaux appropriés, particulièrement provenant de plantes connues pour leurs facultés de résistance ou de vie en milieu pauvre ou pour leur teneur élevée en nucléotides. Suivant la présente invention, on a maintenant trouvé de manière étonnante que l'on peut utiliser une association d'extraits végétaux à base de Groseille à Maquereau, d'Orchi¬ dée Noire et de Tulipe Noire pour la préparation d'une application topique destinée au traitement ou à la prévention des dommages liés au vieillissement de la peau. En fait, on a observé que ledit extrait végétal augmente le taux de protéo- glycanes péri-membranaires, transmembranaires et matriciels et augmente en outre le taux de collagène des fibroblastes dermiques humains. On peut donc l'utiliser à titre de compo¬ sition cosmétique anti-âge. Ainsi, on peut procéder à l'appli¬ cation topique de la composition selon l'invention sur une zone de la peau pour contrebalancer la perte de renouvellement des cellules et la perte des fonctions du derme. La présente invention a donc pour objet une association d'extraits végétaux à base de Groseille à Maquereau, d'Orchi¬ dée Noire et de Tulipe Noire. La présente invention a aussi pour objet une composition topique pour le traitement ou la prévention des dommages liés au vieillissement de la peau, comprenant une association selon le premier objet de l'invention indiqué ci-dessus. L'invention a encore pour objet de proposer l'utilisation d'une association comme ci-dessus, pour la préparation d'une composition topique destinée à lutter contre les dommages liés au vieillissement de la peau. Enfin, la présente invention a également pour objet un procédé cosmétique pour combattre les dommages liés au vieil¬ lissement de la peau, qui comprend une étape consistant à appliquer à des zones de la peau affectées une composition contenant une quantité efficace de la composition topique selon le deuxième objet de la présente invention. Le procédé cosmétique pour l'amélioration de l'aspect externe comprenant une étape consistant à appliquer cette composition topique aux zones de la peau affectées, constitue également un autre objet de la présente invention. On peut utiliser ces compositions topiques de façon avantageuse en dermatologie ou cosmétologie pour le traitement ou la prévention des dommages liés au vieillissement de la peau, plus particulièrement comprenant la perte de la fermeté et de la tonicité de la peau, et l'apparition de rides et ridules. Dans ce qui suit, à des fins de simplification, la composition topique est utile dans un but dermatologique ou cosmétique, sauf indication contraire. Davantage de détails sont donnés ci-après sur les plantes dont sont issus les extraits végétaux à la base de l'asso¬ ciation selon la présente invention. La Groseille à Maquereau est notamment connue pour sa forte teneur en polyphénols (RIBES UVA CRISPA) . Le groseillier à Maquereau est originaire d'Asie et est devenu sub-spontané en Europe du Nord et de l'Est. On le trouve en plaine ou en basse montagne colonisant les milieux pauvres ou encore les terrains spécifiquement acides. Par exemple on le trouve dans les Vosges jusqu'à 1000 m d'altitude ainsi que sur les berges de la Loire en zone inondable. C'est le fruit qui est utilisé. L'Orchidée Noire (Cycnoches Cooperi) , comme toutes les orchidées, vit en milieu pauvre et des écorces de pin ou des débris de lichen peuvent suffire à son développement. Il ne lui faut comme élément essentiel que la lumière, l'humidité et la chaleur. Elle est capable de stocker les matières nutri¬ tives et l'humidité. L'Orchidée Noire est particulièrement riche en flavonoïdes qui ont un intérêt particulier comme piégeurs de radicaux libres et protecteurs meinbranaires. C'est la plante entière qui est utilisée. La Tulipe Noire (Tulipa Nigra) est la plante qui contient le plus d'ADN végétal. C'est une tulipe cultivée. Son origine des régions montagneuses du Nord de l'Europe et de l'Asie explique ses grandes qualités de résistance et de repro¬ duction, ainsi qu'une grande résistance aux UV. C'est un extrait des pétales qui est utilisé. Ces extraits végétaux peuvent être caractérisés par leur teneur en extrait sec et/ou par leur teneur en actif. Les extraits sont avantageusement des extraits hydro- glycoliques ou hydro-alcooliques, par exemple obtenus par macération à froid dans un mélange eau/propylène glycol ou eau/éthanol. Typiquement, les extraits détaillés ci-après peuvent être utilisés pour la préparation de l'association selon la présente invention.The present invention relates to an association based plant extracts of gooseberry, black orchid and black tulip, and a topical composition containing it, and more particularly a composition containing such an association, useful for the treatment and the prevention of damage related to the aging of the skin, as well as the associated cosmetic processes. The skin has several integrated layers, ranging from the superficial layer, the epidermis, to the deeper layers, the dermis and the hypodermis, and each has specific properties allowing the whole to react and adapt to conditions of its environment. The epidermis is mainly composed of three types of cells which are keratinocytes (90% of epidermal cells), melanocytes (2 to 3% of epidermal cells) and Langerhans cells. Its thickness varies according to the different parts of the body. The epidermis, which constitutes the outer layer, plays a fundamental role in ensuring the protection and maintenance of good trophicity. This is why many compositions have been developed to protect and improve its functions, including strengthening its elasticity and firmness. The dermis is thick, solid, rich in nerves and blood vessels and sweat glands. It protects and repairs damaged tissues. This layer consists mainly of collagen, elastin and proteoglycans. These three types of molecules are synthesized by dermal fibroblasts. Collagen fibers, which represent 70% of the dry weight of the dermis, form a support network responsible for the mechanical characteristics of the skin such as strength and texture. Elastin is responsible for elasticity and proteoglycans play a major role in structure and hydration of the skin. Other cells such as macrophages and leucocytes are also present in the dermis layer. The hypodermis, attached to the bottom of the dermis, is the deepest layer of the skin. It contains lipid-producing fat cells to produce a fat layer that protects the muscles, bones, and internal organs from shock, and acts as an insulator and energy source during periods of time. young. One of the first signs of skin aging is a loss of elasticity and the formation of fine lines and wrinkles, which are a direct result of the deterioration of the dermis layer of support. In fact, the ability of the skin to replace damaged collagen decreases and more spaces and irregularities develop in the collagen network. The appearance of pigment marks, the fineness of the skin and the sagging of the skin are also changes observed during the subsequent aging of the skin. Many factors contribute to accelerating the breakdown of collagen, particularly sun exposure, free radicals, certain hormonal changes associated with old age, and tobacco. The aging of the skin is often described as appearing in two ways. The first is chronological or intrinsic aging, while the second is extrinsic aging, namely aging caused by the environment; this is particularly the case of photoaging, which is the damage done to the skin because of the direct or indirect effects of ultraviolet light. The present invention relates not only to intrinsic aging, but also to extrinsic aging. At the skin level, aging causes in particular a decrease in protein synthesis (collagen, elastin) a decrease in the synthesis of proteoglycans among others, as well as an elevation of metalloproteinases of MMP3 type. In addition, oxidation phenomena (free radical content) lead to inflammatory processes that increase skin sensitivity. To combat the aging of the skin, it has been proposed certain cream-based treatments containing alpha-hydroxy acids or retinoids, applied regularly to reduce the number of fine lines in the long term. Collagen implants have also been proposed to conceal expression lines around the eyes or mouth, dermabrasion and chemical peels to remove the upper layer of damaged skin, cosmetic surgery, such as blepharoplasty (surgical procedures). eyelids) or a facelift to rejuvenate sagging skin, or a restructuring with a carbon dioxide laser to remove fine lines and improve scars. Patent application WO 02069992 lists a large number of plant extracts obtained under particular conditions where the plant is previously subjected to stress, and likely to provide an inhibitory effect of certain extracellular proteases and consequently to limit the effects harmful to these proteases. The use of certain plant extracts in cosmetic compositions is also described in patent applications JP 02279618 relating to water-soluble extracts of orchid with moisturizing action, JP 2003040758 relating to extracts of saxifrage and JP 10007582 relating to extracts of tulip. However, there is still an increased need to find alternative topical compositions that effectively fight against skin aging, and in particular to find topical compositions based on appropriate plant extracts, particularly from plants known for their resistance or life in poor environment or for their high content of nucleotides. In accordance with the present invention, it has now surprisingly been found that a combination of vegetable extracts of gooseberry, black orchid and black tulip can be used for the preparation of a topical application for the treatment or prevention of damage related to aging of the skin. In fact, it has been observed that said plant extract increases the level of per membrane, transmembrane and matrix proteoglycans and further increases the collagen level of human dermal fibroblasts. It can therefore be used as an anti-aging cosmetic composition. Thus, it is possible to apply topically the composition according to the invention to an area of the skin to counterbalance the loss of renewal of the cells and the loss of dermal functions. The subject of the present invention is therefore an association of vegetable extracts based on gooseberry, black orchid and black tulip. The present invention also relates to a topical composition for the treatment or prevention of damage related to aging of the skin, comprising an association according to the first subject of the invention indicated above. The invention also aims to propose the use of an association as above, for the preparation of a topical composition for combating skin aging damage. Finally, the subject of the present invention is also a cosmetic process for combating skin aging damage, which comprises the step of applying to a region of the affected skin a composition containing an effective amount of the topical composition according to the second object of the present invention. The cosmetic process for improving the external appearance comprising a step of applying this topical composition to the areas of the affected skin is also another object of the present invention. These topical compositions can advantageously be used in dermatology or cosmetology for the treatment or prevention of damage associated with aging of the skin, more particularly including the loss of skin firmness and tone, and the appearance of wrinkles. and fine lines. In what follows, for the purpose of simplification, the topical composition is useful for dermatological or cosmetic purposes, unless otherwise indicated. More details are given hereinafter on the plants from which the plant extracts are derived at the base of the combination according to the present invention. The gooseberry is particularly known for its high content of polyphenols (RIBES UVA CRISPA). The gooseberry in Maquereau originates from Asia and has become sub-spontaneous in Northern and Eastern Europe. It is found in plain or low mountain colonizing poor environments or even specifically acidic terrains. For example it is found in the Vosges up to 1000 m altitude and on the banks of the Loire in flood zone. It is the fruit that is used. The Black Orchid (Cycnoches Cooperi), like all orchids, lives in poor conditions and pine bark or debris of lichen may be sufficient for its development. It only needs as an essential element light, moisture and heat. It is able to store nutri¬ tive materials and moisture. The Black Orchid is particularly rich in flavonoids which have a particular interest as scavengers of free radicals and protectors meinbranaires. It is the whole plant that is used. The Black Tulip (Tulipa Nigra) is the plant that contains the most plant DNA. It is a cultivated tulip. Its origin in the mountainous regions of northern Europe and Asia explains its great qualities of resistance and repro¬ duction, as well as a great resistance to UV. It is an extract of the petals that is used. These plant extracts can be characterized by their dry extract content and / or by their active content. The extracts are advantageously hydro-glycol or hydro-alcoholic extracts, for example obtained by cold maceration in a water / propylene glycol or water / ethanol mixture. Typically, the extracts detailed below may be used for the preparation of the combination according to the present invention.
Extrait de Groseille à Maquereau - Eau / Ethanol 50/50 - Matière sèche 1,8% - Polyphénols (sur matière sèche) 0,13% - Flavonoïdes (sur matière sèche) 0,05%Gooseberry Extract - Water / Ethanol 50/50 - Dry matter 1,8% - Polyphenols (on dry matter) 0,13% - Flavonoids (on dry matter) 0,05%
Extrait d'Orchidée Noire - Eau / propylène glycol 50/50 - Matière sèche 0,20% - Flavonoïdes (sur matière sèche) 0,05%Black Orchid Extract - Water / propylene glycol 50/50 - Dry matter 0,20% - Flavonoids (on dry matter) 0,05%
Extrait de pétales de Tulipe Noire - Eau / propylène glycol 50/50 - Matière sèche 0,6% - ADN (présence) L'association peut également prendre la forme d'extraits huileux qui peuvent être obtenus par macération des plantes dans des triglycérides capriques/capryliques, du tournesol oléique ou tout mélange polaire/apolaire du type huile de noyau d'abricot / huile de vaseline. On peut ainsi extraire les matières liposolubles telles que des flavones et certains polyphénols. Les compositions topiques selon l'invention peuvent se présenter sous toute formulation cosmétique. Les compositions topiques selon l'invention peuvent par exemple comprendre des excipients appropriés pour une administration topique externe, en particulier des excipients acceptables sur le plan dermatologique. Ces excipients appropriés pour la formulation sont bien connus de l'homme du métier et comprennent en particulier les épaississants tels que les gommes naturelles et les polymères de synthèse ; les émollients et les tensio-actifs tels que l'octanoate de cétéaryle, le myristate d'isopropyle, 1 'isononanoate de cétéaryle, la diméthicone, la cyclométhicone, le 3-diiso- stéarate de polyglycéryle, le polyisobutène hydrogéné, l'alcool cétylique, le palmitate cétylique, le phosphate cétylique ; les émulsifiants ; les conservateurs tels que le phénoxyéthanol, le parahydroxybenzoate de méthyle (méthyl- paraben) , le parahydroxybenzoate de propyle (propylparaben) et le Phenonip® associant du phénoxyéthanol et des parahydroxy- benzoates de méthyle, éthyle, butyle et isobutyle ; les colorants ; les parfums ; etc. D'autres ingrédients peuvent être utilisés dans les compositions : les agents hydratants tels que le propylène glycol, la glycérine, le butylène glycol et également les vitamines antioxydantes telles que la vitamine E, par exemple l'acétate de tocophérol ou le tocotriénol, la vitamine C, les polyphénols naturels. On peut également ajouter à la composition des agents conditionneurs de la peau tels que le nylon. Les compositions topiques selon l'invention peuvent être sous la forme d'une solution, d'une lotion hydrophile, d'une pommade, d'une crème, d'un sérum ou d'un gel. Les compositions peuvent également être, par exemple, sous forme d'émulsions huile dans eau, eau dans huile ou multiples, de produits moussants ou sous une forme de liposomes. On peut aussi appliquer sur la peau toutes les compositions telles que décrites ci-dessus au moyen de lingettes. Les compositions topiques selon l'invention peuvent de plus inclure un ou plusieurs d'une diversité d'ingrédients facultatifs, tels que des agents colorants, des agents opacifiants et analogues. Dans l'association selon le premier but de l'invention chacun des extraits végétaux de Groseille à Maquereau, d'Orchidée Noire et de Tulipe Noire, est avantageusement présent dans une teneur comprise entre 5 et 90%, ces teneurs étant exprimées par rapport au poids total de l'association. De préférence, ces teneurs sont d'environ 25 à 50%, et plus préférentiellement on utilise une association comprenant les trois extraits en quantités sensiblement égales. Les compositions topiques selon l'invention incluent typiquement entre 0,1% et 20% (p/p) en poids de l'association selon la présente invention par rapport au poids total de la composition topique, et de préférence de 2% à 8%. Suivant une forme avantageuse de réalisation, les extraits constituant l'association de l'invention sont complétés par des principes actifs ou ingrédients auxiliaires choisis pour leurs propriétés complémentaires, afin de renfor¬ cer les effets anti-âge de la composition. Ainsi il est particulièrement avantageux de les combiner avec des quantités appropriées d'une antihyaluronidase telle que Echinacine B afin de générer un maximum d'eau liée, d'Imperata cylindrica, par exemple MOIST 24® de la société Sederma, afin de favoriser l'hydratation de la peau par modification de la pression osmotique, des protéines de graines d'amarante (Amarantus caudatus) ou des globulines de pois afin d'obtenir un effet tenseur de la peau, de l'huile de Calophylum afin de renforcer l'effet anti-rides, de l'huile d'Echium pour son effet anti¬ inflammatoire, ou encore un palmitoyl pentapeptide-3 tel que le Matrixyl® ou des dérivés tels que le palmitoyl GHK (possédant la chaîne Glycyl-Histidyl-Lysine) et le palmitoyl GQPR (Glycyl-Glutamyl-Prolyl-Arginine) ou le palmitoyl VGVAPG (Valyl-Glycyl-Valyl-Alanyl-Prolyl-Glycine) associé à un céra- mide-2, ainsi que d'une manière générale toute association avec un céramide. Les compositions topiques selon l'invention ont un effet d'amélioration des dommages cutanés dus au vieillissement. On peut obtenir les premiers résultats après 2 à 3 semaines de traitement quotidien en appliquant une à deux fois par jour les compositions sur les zones de la peau à traiter. Lesdites compositions de l'invention peuvent être choisies pour une utilisation de jour et/ou de nuit sur le visage, le corps et les mains. Les compositions selon l'invention sont particulièrement appropriées pour le traitement des zones de contour des yeux et des lèvres, qui sont très fragiles et hautement suscepti¬ bles de voir apparaître des rides et une perte de la fermeté de la peau. Les compositions selon l'invention sont très bien tolérées sur cette zone sensible, et rendent possible une réduction visible du nombre de rides et de marques aux yeux, ainsi qu'un raffermissement de la peau particulièrement sensible du contour des yeux et de la bouche. Les exemples qui suivent illustrent la présente inven¬ tion, sans en limiter la portée. Des exemples de formulations sont rapportés aux exemples 1 à 4. L'exemple 5 est relatif à une étude toxicologique et à des tests d'activité sur les fibroblastes humains, qui ont permis d'évaluer l'effet anti-inflammatoire (interleukines) et l'effet anti-vieillissement (dosage de MPP3, protéoglycanes et collagènes) . Dans les exemples 1 à 4 qui suivent, le "complexe de plante" correspond à une association à base d'extraits végétaux de Groseille à Maquereau, d'Orchidée Noire et de Tulipe Noire selon la présente invention dans laquelle les trois extraits sont ceux détaillés ci-dessus (extrait par macération à froid d'un mélange eau/propylène glycol ou eau/éthanol) et ils sont compris en parties égales. Sauf indication contraire, les compositions sont données en parties en poids. Exemple 1Black Tulip Petals Extract - Water / Propylene Glycol 50/50 - Dry Matter 0.6% - DNA (Presence) The combination may also take the form of oily extracts that can be obtained by macerating the plants in capric triglycerides / caprylic, oleic sunflower or any polar / apolar mixture of the type of apricot kernel oil / Vaseline oil. It is thus possible to extract liposoluble materials such as flavones and certain polyphenols. The topical compositions according to the invention may be in any cosmetic formulation. The topical compositions according to the invention may for example comprise excipients suitable for external topical administration, in particular excipients dermatologically acceptable. These excipients suitable for the formulation are well known to those skilled in the art and include in particular thickeners such as natural gums and synthetic polymers; emollients and surfactants such as cetearyl octanoate, isopropyl myristate, cetearyl isononanoate, dimethicone, cyclomethicone, polyglyceryl 3-diisostearate, hydrogenated polyisobutene, cetyl alcohol cetyl palmitate, cetyl phosphate; emulsifiers; preservatives such as phenoxyethanol, methyl parahydroxybenzoate (methyl paraben), propylparaben parahydroxybenzoate and Phenonip® associating phenoxyethanol and methyl, ethyl, butyl and isobutyl parahydroxybenzoates; dyes; the perfumes ; etc. Other ingredients may be used in the compositions: moisturizing agents such as propylene glycol, glycerol, butylene glycol and also antioxidant vitamins such as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols. Skin conditioning agents such as nylon can also be added to the composition. The topical compositions according to the invention may be in the form of a solution, a hydrophilic lotion, an ointment, a cream, a serum or a gel. The compositions may also be, for example, in the form of oil-in-water, water-in-oil or multiple emulsions, foaming products or in the form of liposomes. It is also possible to apply to the skin all the compositions as described above by means of wipes. The topical compositions according to the invention may further include one or more of a variety of ingredients optional, such as coloring agents, opacifying agents and the like. In the association according to the first object of the invention, each of the vegetable extracts of gooseberry, black orchid and black tulip is advantageously present in a content of between 5 and 90%, these contents being expressed relative to total weight of the association. Preferably, these contents are approximately 25 to 50%, and more preferably an association comprising the three extracts in substantially equal amounts is used. The topical compositions according to the invention typically comprise between 0.1% and 20% (w / w) by weight of the combination according to the present invention relative to the total weight of the topical composition, and preferably from 2% to 8% by weight. %. According to an advantageous embodiment, the extracts constituting the combination of the invention are supplemented with active ingredients or auxiliary ingredients chosen for their complementary properties, in order to reinforce the anti-aging effects of the composition. Thus, it is particularly advantageous to combine them with appropriate amounts of an antihyaluronidase such as Echinacin B in order to generate a maximum of bound water, of Imperata cylindrica, for example MOIST 24® from Sederma, in order to favor the hydration of the skin by modification of the osmotic pressure, amaranth seed protein (Amarantus caudatus) or pea globulins to obtain a skin tightening effect, Calophylum oil to enhance the effect anti-wrinkles, Echium oil for its anti-inflammatory effect, or palmitoyl pentapeptide-3 such as Matrixyl® or derivatives such as palmitoyl GHK (having the glycyl-Histidyl-Lysine chain) and the palmitoyl GQPR (Glycyl-Glutamyl-Prolyl-Arginine) or palmitoyl VGVAPG (Valyl-Glycyl-Valyl-Alanyl-Prolyl-Glycine) combined with a ceramide-2, as well as in general any combination with a ceramide. The topical compositions according to the invention have an effect of improving cutaneous damage due to aging. The first results can be obtained after 2 to 3 weeks of daily treatment by applying the compositions once or twice a day to the areas of the skin to be treated. Said compositions of the invention may be chosen for day and / or night use on the face, body and hands. The compositions according to the invention are particularly suitable for the treatment of the contour areas of the eyes and lips, which are very fragile and highly susceptible to the appearance of wrinkles and loss of firmness of the skin. The compositions according to the invention are very well tolerated on this sensitive area, and make possible a visible reduction in the number of wrinkles and marks on the eyes, as well as a particularly sensitive skin firming of the eye and mouth contours. The following examples illustrate the present invention without limiting its scope. Examples of formulations are reported in Examples 1 to 4. Example 5 relates to a toxicological study and to tests of activity on human fibroblasts, which made it possible to evaluate the anti-inflammatory effect (interleukins) and the anti-aging effect (MPP3 assay, proteoglycans and collagens). In Examples 1 to 4 which follow, the "plant complex" corresponds to an association based on vegetable extracts of gooseberry, black orchid and black tulip according to the present invention in which the three extracts are those detailed. above (extracted by cold maceration of a mixture of water / propylene glycol or water / ethanol) and they are included in equal parts. Unless otherwise indicated, the compositions are given in parts by weight. Example 1
Lotion tonique calmante et hydratante Eau de Rosés 5, 0 Eau de Bleuet 10, 0 Eau d'Hamamelis 10,0 Butylène glycol 1-3 5,0 Glycérine 5,0 Lactate de sodium 2,0 Complexe de plantes suivant l'invention 3,0 Phenonip 0,5 Eau de laitue 5,0 Eau déminéralisée QSP 100,0Calming and moisturizing tonic lotion Eau de Rosés 5, 0 Cornflower water 10, 0 Hamamelis water 10.0 Butylene glycol 1-3 5.0 Glycerine 5.0 Sodium lactate 2.0 Plant complex according to the invention 3 , 0 Phenonip 0.5 Lettuce water 5.0 Demineralized water QSP 100.0
Exemple 2Example 2
Crème de jour éclat hydratante Eau déminéralisée QSP 100,0 Glycérine 5,0 Butylène glycol 1-3 4,0 Complexe de plantes suivant l'invention 5,0 Extrait de levure 2,0 Extrait d' Imperata cylindrica 3,0 Protéines d'Amarante 1,0 Huile de noisettes 5,0 Huile de pépins de framboises 0,5 Huile de noyau de cerise aminés 1,0 Perhydrosqualène . 5,0 Polysorbate 60 3,5 Stéarate de sorbitan 2,5 Alcool cétostéarylique 4,0 Diméthicone 1,0 Tocophérols 0,5Moisturizing Day Cream Demineralized water QSP 100.0 Glycerin 5.0 Butylene glycol 1-3 4.0 Herbal complex according to the invention 5.0 Yeast extract 2.0 Imperata cylindrica extract 3.0 Proteins Amaranth 1.0 Hazelnut oil 5.0 Raspberry seed oil 0.5 Cherry kernel oil 1.0 Perhydrosqualene. 5.0 Polysorbate 60 3.5 Sorbitan stearate 2.5 Cetostearyl alcohol 4.0 Dimethicone 1.0 Tocopherols 0.5
Exemple 3Example 3
Crème antirides régénérante Eau déminéralisée QSP 100,0 Phenonip 0,7 Glycérine 4,0 Butylène Glycol 1,3 3,0 Sorbitol 70% 2,0 Complexe de plantes suivant l'invention 10,0 Matrixyl (palmitoyl pentapeptide-3) * 3,0 Protéines d'Amarante 2,0 Beurre de Karité 3,0 Huile d'Echium 2,0 Huile de Rosier Muscat 3,0 Huile de Calophylum 2,0 PEG 20 Methyl glucose stéarate 3,5 Methyl glucose stéarate 3,0 Lécithine 1,0 Microcapsules de vitamine A et E 1,0 Ascorbyl sulfate de magnésium 0,3 Propyl Paraben 0,1 * : commercialisé par SedermaRegenerating anti-wrinkle cream Demineralized water QSP 100.0 Phenonip 0.7 Glycerin 4.0 Butylene Glycol 1.3 3.0 Sorbitol 70% 2.0 Plant Complex According to the Invention 10.0 Matrixyl (palmitoyl pentapeptide-3) * 3.0 Amaranth Proteins 2.0 Shea Butter 3.0 Echium 2.0 Rosehip oil Muscat 3.0 Calophylum oil 2.0 PEG 20 Methyl glucose stearate 3.5 Methyl glucose stearate 3.0 Lecithin 1.0 Microcapsules of vitamin A and E 1.0 Ascorbyl magnesium sulfate 0 , 3 Propyl Paraben 0.1 *: marketed by Sederma
Exemple 4 Sérum antirides régénérant Mélange de plantes lyophilisées : - Polyphénols de Groseille Maquereau 0,05 - Extrait d'Orchidée 0,10 - ADN de Tulipe Noire 0,20 - Glycocolle Q, 65 TOTAL 1,00 En flacon lyophilisé Solvant Glycérine 0,5 - Butylène glycol 0,5 Biosaccharide grum-1 1,0 - Phenonip 0,07 - Globulines de pois 2,0 Extrait d' Imperata cylindrica 0,3 Protéines d'Amarante 1,0 - Eau déminéralisée QSP 10,0 La partie lyophilisée est dissoute par le solvant et procure un traitement pour 7 jours.Example 4 Regenerating anti-wrinkle serum Mixture of lyophilized plants: - Polyphenols of Currant Mackerel 0.05 - Orchid Extract 0.10 - DNA of Black Tulip 0.20 - Glycocolin Q, 65 TOTAL 1.00 In lyophilized vial Solvent Glycerin 0, 5 - Butylene glycol 0.5 Biosaccharide grum-1 1.0 - Phenonip 0.07 - Pea Globulins 2.0 Imperata cylindrica extract 0.3 Amaranth Proteins 1.0 - Demineralized Water QSP 10.0 The lyophilized portion is dissolved by the solvent and provides a treatment for 7 days.
Exemple 5 Outre la toxicologie du produit, des études sur les fibroblastes humains en culture ont été menées.Example 5 In addition to the toxicology of the product, studies on human fibroblasts in culture were conducted.
5-1. PROTOCOLE EXPERIMENTAL5-1. EXPERIMENTAL PROTOCOL
1.1. Fibroblastes humains en culture Les cultures de fibroblastes sont établies à partir de peau de prépuces humains récoltés lors de circoncisions et sont amplifiées en milieu de culture RPMI 1640 supplémenté par du sérum de veau fœtal, de la L-glutamine et de la gentamycine. Les fibroblastes ont été ensemencés dans des boites de 25 cm2 à raison de 10δ cellules par ml. Ils ont ensuite été incubés pendant 24 heures. 1.2. Aspect toxicologique Le but de cette première étape était de chercher la cytotoxicité du produit vis-à-vis des fibroblastes humains en culture. La croissance cellulaire est réalisée sur 3 concentrations non cytotoxiques. La cytotoxicité a été réalisée par la détermination de la néosynthèse des protéines. Les fibroblastes humains obtenus par primoculture ont été récupérés après trypsinisation et centrifugation. Le culot cellulaire a été resuspendu dans 10 ml de milieu RPMI 1640 supplémenté avec le sérum de veau fœtal (10%) , de la L-glutamine (8 mM) et de la gentamicine (80 μg/ml) . Après homogénéisation, les cellules ont été réparties dans des plaques multipuits (6 puits) à raison de 1.105 cellules/ml. Les plaques ont été mises à incuber pendant 24 heures. Le milieu a été ensuite éliminé et du milieu frais a été ajouté soit seul, soit additionné de différentes concentrations du produit "complexe de plantes" 0,1%, 0,2%, 0,5%, 1% et 5%) . Les temps de contact du produit avec les cellules étaient de 24 heures. Pour étudier la capacité des cellules préalablement traitées par le produit à incorporer les précurseurs radioactifs dans les protéines, la technique de puise a été adoptée. Les précurseurs radioactifs ont été ajoutés aux cultures après les durées d' incubation avec le produit à différentes concentrations. Les cellules ont été alors incubées pendant deux heures supplémentaires à 370C en présence de 3H-leucine (1 μCi/ml de milieu de culture, activité spécifique : 5 Ci/mmol) . Après avoir éliminé le milieu par aspiration, les cellules ont été lavées deux fois avec du milieu sans sérum pour éliminer la radioactivité non incorporée puis détachées du support par grattage de la surface de culture. Les cellules ont été lavées une nouvelle fois puis centrifugées à 600 g pendant 5 minutes. Le culot cellulaire a été repris dans 500 μl de milieu. Pour la détermination de la radioactivité incorporée dans les macromolécules, on a ajouté 500 μl de NaOH 20% (poids/volume) puis l'ensemble a été soumis à l'hydrolyse pendant 30 minutes à 370C. Les hydrolysats ont ensuite été précipités avec 1 ml d'une solution acide trichloracétique (TCA) à 40%. Les préparations sont laissées une heure à 40C. Les échantillons ont été filtrés sur filtre en fibre de verre (Whatman GF/A) monté en appareil Millipore. Les filtres ont été lavés trois fois avec 10 ml de TCA 5% et deux fois avec de l'éthanol 95% puis introduits dans des flacons de comptage et séchés pendant 30 minutes à 8O0C. La radioactivité a été mesurée dans un compteur à scintillation liquide en présence de 5 ml de scintillateur liquide (Ready organique, Beckman) contenant 0,9% d'acide acétique. 1.3. Dosage des médiateurs de l'inflammation (ILl-a, IL- 6, TNF-a) A la fin du temps d'incubation (24 heures), les milieux de culture ont été prélevés, et le dosage de l'ILl-a et de 1' IL-6 a été réalisé conformément aux protocoles décrits dans les kits de dosages : - Kit de détection interleukine 1-A (Ill-a) /R&D Systèmes - Kit de détection interleukine 6 (111-6) /R&D Systèmes 1.4. Evaluation de l'effet de produit sur les consti¬ tuants de la matrice extracellulaire des fibroblastes humains1.1. Human fibroblasts in culture The fibroblast cultures are established from human foreskin skin harvested during circumcisions and are amplified in RPMI 1640 culture medium supplemented with fetal calf serum, L-glutamine and gentamycin. The fibroblasts were seeded in boxes of 25 cm 2 at a rate of 10 δ cells per ml. They were then incubated for 24 hours. 1.2. Toxicological aspect The purpose of this first step was to seek the cytotoxicity of the product with respect to human fibroblasts in culture. The cell growth is carried out on 3 non-cytotoxic concentrations. Cytotoxicity was achieved by determining neosynthesis of proteins. Human fibroblasts obtained by primoculture were recovered after trypsinization and centrifugation. The cell pellet was resuspended in 10 ml of RPMI 1640 medium supplemented with fetal calf serum (10%), L-glutamine (8 mM) and gentamicin (80 μg / ml). After homogenization, the cells were distributed in multiwell plates (6 wells) at a rate of 1.10 5 cells / ml. The plates were incubated for 24 hours. The medium was then removed and fresh medium was added either alone or supplemented with different concentrations of the "plant complex" product 0.1%, 0.2%, 0.5%, 1% and 5%). The contact times of the product with the cells were 24 hours. To study the capacity of the cells previously treated with the product to incorporate the radioactive precursors into the proteins, the pulsation technique was adopted. Radioactive precursors were added to the cultures after the incubation times with the product at different concentrations. The cells were then incubated for an additional two hours at 37 ° C. in the presence of 3 H-leucine (1 μCi / ml of culture medium, specific activity: 5 Ci / mmol). After removing the medium by aspiration, the cells were washed twice with serum-free medium to remove unincorporated radioactivity and then detached from the support by scratching the culture surface. The cells were washed again and then centrifuged at 600 g for 5 minutes. The cell pellet was taken up in 500 μl of medium. For the determination of the radioactivity incorporated into the macromolecules, 500 μl of 20% (w / v) NaOH were added, and then the whole was subjected to hydrolysis for 30 minutes at 37 ° C. The hydrolysates were then precipitated. with 1 ml of a 40% trichloroacetic acid (TCA) solution. The preparations are left for one hour at 40 ° C. The samples were filtered on a fiberglass filter (Whatman GF / A) mounted in Millipore apparatus. The filters were washed three times with 10 ml of 5% TCA and twice with 95% ethanol and then introduced into counting flasks and dried for 30 minutes at 80 ° C. The radioactivity was measured in a counter. liquid scintillation in the presence of 5 ml of liquid scintillator (organic Ready, Beckman) containing 0.9% acetic acid. 1.3. Assay of Inflammation Mediators (IL-1α, IL-6, TNF-α) At the end of the incubation time (24 hours), the culture media were removed, and the IL-α assay was assayed. and IL-6 was carried out according to the protocols described in the assay kits: - Interleukin Detection Kit 1-A (Ill-a) / R & D Systems - Interleukin Detection Kit 6 (111-6) / R & D Systems 1.4. Evaluation of the effect of product on the constituents of the extracellular matrix of human fibroblasts
1.4.1. Etude de l'effet du produit sur les protéoglycanes synthétisés par les fibroblastes humains. Pour cette étude, les fibroblastes ont été utilisés en grand nombre pour avoir une quantité suffisante de protéo¬ glycanes et de glycosaminoglycanes. Les fibroblastes ont été répartis dans des boîtes multipuits (6 puits) à raison de 2.105/ml dans 3 ml de milieu de culture. Elles ont ensuite été maintenues 24 heures en étuves à CO2. Afin d'étudier la capacité des cellules, préalablement traitées par la substance, à incorporer le précurseur radioactif, la technique de puise a été adoptée. Le précurseur radioactif ([3H]- Glucosamine) a été rajouté aux cultures 18 heures avant la récupération des cellules. Le temps de contact des cellules avec le produit a été de 24 heures à 370C. Après avoir éliminé le milieu par aspiration, les cellules ont été lavées 2 fois avec du milieu sans sérum pour éliminer la radioactivité non incorporée, puis détachées du support par grattage de la surface de la culture. Les cellules ont été lavées une nouvelle fois avec du milieu puis recentrifugées à 600 g pendant 5 minutes. A partir de ce culot final ont été réalisés : - le dosage des protéoglycanes par FPLC (Fast Protein Liquid Chromatography) - la néosynthèse des glycosaminoglycanes totaux (GAGs) - le dosage des protéines totales1.4.1. Study of the effect of the product on proteoglycans synthesized by human fibroblasts. For this study, fibroblasts were used in large numbers to have a sufficient amount of proteoglycans and glycosaminoglycans. The fibroblasts were distributed in multiwell wells (6 wells) at a rate of 2.10 5 / ml in 3 ml of culture medium. They were then kept for 24 hours in CO 2 ovens. In order to study the capacity of the cells, previously treated with the substance, to incorporate the radioactive precursor, the pulsation technique was adopted. The radioactive precursor ([3H] - Glucosamine) was added to the cultures 18 hours before cell recovery. The contact time of the cells with the product was 24 hours at 37 ° C. After removing the medium by suction, the cells were washed twice with serum-free medium to eliminate the unincorporated radioactivity, and then detached from the support. by scratching the surface of the crop. The cells were washed again with medium and then recentrifuged at 600 g for 5 minutes. From this final pellet were made: - the proteoglycan assay by FPLC (Fast Protein Liquid Chromatography) - the neosynthesis of total glycosaminoglycans (GAGs) - the total protein assay
ExtractionExtraction
Protéoglycanes péri-membranaires Une première fraction du culot a été resuspendu dans NaCl IM contenant la désoxyribonucléase (50 U/ml) et des inhibiteurs de protéases. L'homogénat a ensuite été incubé à 4°C pendant 2 heures. Une centrifugation pendant 30 minutes à 12 000 g a permis d'obtenir le premier homogénat contenant les protéoglycanes péri-membranaires. Le culot a servi à extraire les protéoglycanes des 2 autres compartiments (Cl) . Protéoglycanes tratis-meπibranaires Le culot Cl obtenu à partir de la première étape d'extraction a été resuspendu dans l'azide sodium 0,1% contenant du désoxycholate de sodium (DOC : 4%) , soniqué à 75 mv pendant 20 secondes puis incubé 2 heures à 40C. Une centrifugation pendant 30 minutes à 12 000 g a permis d' obtenir le deuxième surnageant contenant les protéoglycanes trans-membranaires. Le culot a servi à extraire les protéo¬ glycanes du compartiment matriciel (C2) .Perimembrane Proteoglycans A first fraction of the pellet was resuspended in 1M NaCl containing deoxyribonuclease (50 U / ml) and protease inhibitors. The homogenate was then incubated at 4 ° C for 2 hours. Centrifugation for 30 minutes at 12,000 g allowed to obtain the first homogenate containing peri-membrane proteoglycans. The pellet was used to extract the proteoglycans from the other 2 compartments (Cl). Tratis-meπibranar proteoglycans The C1 pellet obtained from the first extraction step was resuspended in sodium azide containing sodium deoxycholate (DOC 4%), sonicated at 75 mV for 20 seconds and then incubated. 2 hours at 40.degree. C. Centrifugation for 30 minutes at 12000 g allowed to obtain the second supernatant containing trans-membrane proteoglycans. The pellet was used to extract the proteo¬ glycans from the matrix compartment (C2).
Protéoglycanes matriciels Le culot C2 a été lavé trois fois avec l'azide de sodium 0,1% puis a été remis en suspension sous agitation dans un tampon acétate de sodium 50 mM contenant la guanidine HCl 4 M et du triton X-100 0,1% ainsi que des inhibiteurs de protéases. Une centrifugation pendant 30 minutes à 12 000 g a permis d'obtenir le troisième surnageant contenant les protéoglycanes matriciels.Matrix proteoglycans The C2 pellet was washed three times with 0.1% sodium azide and then resuspended with stirring in a 50 mM sodium acetate buffer containing 4 M guanidine HCl and triton X-100 0, 1% as well as protease inhibitors. Centrifugation for 30 minutes at 12,000 g yielded the third supernatant containing the matrix proteoglycans.
Purification par FPLCFPLC purification
Préalablement à la purification par FPLC, chacun des 3 surnageants a été précipité une nuit à 40C dans un volume d'éthanol absolu, puis centrifugés à 12 000 g pendant 30 minutes . Les culots obtenus ont été resuspendus dans un tampon tris-HCL 5OmM pH 7,4. Le même protocole d'analyse a été réalisé pour 3 solutés. La chromatographie échangeuse d' anions a été utilisée. Chaque culot a été resuspendu dans 250 ml du tampon Tris-HCL 50 mM pH 7,4. Le gel sepharose CL-6B (DEAE) (Pharmacia) a été coulé dans une colonne K 10/40 (Pharamcia) . Le gel échangeur d'anions a une grande résolution et un bon rendement. 100 μl de chaque échantillon ont été injectés ; L'élution est suivie par détection au spectrofluomètre à longueur d'onde 280 nm. Le pic contenant les protéoglycanes est élue à 1 M de NaCl. DosagePrior to purification by FPLC, each of the 3 supernatants was precipitated overnight at 40 ° C. in a volume of absolute ethanol and then centrifuged at 12,000 g for 30 minutes. The pellets obtained were resuspended in a 5mM Tris-HCl buffer pH 7.4. The same analysis protocol was performed for 3 solutes. Anion exchange chromatography was used. Each pellet was resuspended in 250 ml of 50 mM Tris-HCl buffer pH 7.4. Sepharose gel CL-6B (DEAE) (Pharmacia) was cast in a K 10/40 column (Pharamcia). The anion exchange gel has a high resolution and a good yield. 100 μl of each sample were injected; Elution is monitored by 280 nm wavelength spectrofluorometer detection. The peak containing the proteoglycans is eluted at 1 M NaCl. dosage
Le dosage de la radioactivité est réalisé à la sortie d'HPLC grâce à un compteur Packard (Flow-one) .The radioactivity assay is performed at the HPLC outlet using a Packard meter (Flow-one).
1.4.2. Etude de l'effet du produit sur les glycosam±noglycanes synthétisés par les fibroblastes humains Une deuxième fraction du culot a été traitée par la pronase 1 mg/ml pendant 24 heures à 60°C. La réaction a été stoppée par refroidissement des tubes. Les protéines ont été précipitées par du TCA 12% à 40C pendant une nuit. Les précipités ont ensuite été centrifugés à 12 000 g pendant 30 minutes. Les surnageant contenant les glycosaminoglycanes ont été récupérés, dialyses contre de l'eau ultra pure (MiIIiQ plus), puis lyophilisés. Les lyophilisats ont ensuite été resuspendus dans un tampon Tris-HCl pH 7,4 contenant des inhibiteurs de protéases. Un aliquote de 50 μl a été prélevé pour le comptage de la radioactivité incorporée dans les glycosaminoglycanes totaux.1.4.2. Study of the effect of the product on the glycosaminoglycans synthesized by human fibroblasts A second fraction of the pellet was treated with pronase 1 mg / ml for 24 hours at 60 ° C. The reaction was stopped by cooling the tubes. The proteins were precipitated by TCA 12% to 4 0 C overnight. The precipitates were then centrifuged at 12,000 g for 30 minutes. The supernatants containing the glycosaminoglycans were recovered, dialyzed against ultra pure water (MiIIiQ plus), and then lyophilized. The lyophilizates were then resuspended in Tris-HCl buffer pH 7.4 containing protease inhibitors. A 50 μl aliquot was taken for counting the radioactivity incorporated into the total glycosaminoglycans.
1.4.3. Etude de l'effet du produit sur la néo synthèse du collagène synthétisés par les fibroblastes humains Pour cette étude les fibroblastes ont été cultivés de la même façon que dans le paragraphe 1.4.1. Après le temps d'incubation, les fibroblastes sont récupérés par centrifugation. Les culots sont digérés par les collagènes (1 mg/culot cellulaire) dans l'acide acétique 0,5 ml/1 pendant 24 heures à 40C. Après centrifugation à 10 000 g, les collagènes sont précipités par le chlorure de sodium (NaCl) à 1 M, le précipité est resuspendu puis dialyse. Les acides aminés primaires sont dérivés par l'acide ophtaldéhyde (OPA) éliminant ainsi leur interférence. L'hydroxyproline et la proline sont alors dérivées par le NBD-Cl par couplage des groupements aminés au NBD-Cl. Le NBD-Hyp est séparé et identifié par le HPLC en phase inverse. Pour la mise au point de la séparation des dérivés d'acides aminés, un couplage au NBD-CL d'un standard contenant 1'hydroxyproline est d'abord réalisé. - L'hydroxyproline est dosée par mesure de la fluorescence après séparation HPLC en phase inverse : o Injecteur automatique o Colonne Ultrasep C18 (30cm*0, 18cm) o 6 μm de porosité o Détecteur de fluorescence La phase mobile est constituée d'un mélange d' acétonitrile/tampon phosphate de sodium 0,1 mol/1, pH 7,2 (9:91 v/v) , le débit est réglé a 1 ml/min, l'élution est réalisée en mode statique et le cycle est de 10 minutes. La phases mobile est préalablement filtrée, puis dégazée avant utilisation. - Les solutions sont préparées de la façon suivante : NBD-Cl : 25 mmol dissous dans le méthanol, OPA = 150 mmol/1 dissous dans du méthanol, Tampon phosphate = 0,4 mmol/1, pH ajusté à 7,2. La gamme étalon est préparée à partir d' une solution d'hydroxyproline à 50 mg/1. Les dilutions successives permettent d'obtenir des solutions allant de 0,5 à 40 mg/1. La dérivatisation et l'établissement de la courbe d'étalonnage sont effectués à partir de 10 μl d'une solution étalon à différentes concentrations mélangée avec 10 μl du tampon. Après addition de 5 μl d'OPA et agitation, les tubes sont gardés 5 min à température ambiante puis 10 μl de la solution NBD-Cl sont ajoutés. Le dérivât se fait à 60°C, au bain marie, pendant 3 minutes, à l'abri de la lumière. Les tubes sont ensuite retirés et la coloration orange permet de vérifier la dérivatisation. Ils sont, par la suite, mis dans la glace afin d'assurer le refroidissement. 50 μl de ce mélange sont ensuite injectés dans la colonne afin d'obtenir la courbe d'étalonnage qui doit être linéaire. Les échantillons sont traités de la même façon.1.4.3. Study of the effect of the product on the neo synthesis of collagen synthesized by human fibroblasts For this study the fibroblasts were cultured in the same way as in section 1.4.1. After the incubation time, the fibroblasts are recovered by centrifugation. The pellets are digested with collagen (1 mg / cell pellet) in acetic acid 0.5 ml / 1 for 24 hours at 4 ° C. After centrifugation at 10,000 g, the collagens are precipitated by sodium chloride ( 1M NaCl), the precipitate is resuspended and then dialyzed. The primary amino acids are derived by ophthaldehyde acid (OPA) thus eliminating their interference. Hydroxyproline and proline are then derived by NBD-Cl by coupling of the amino groups to NBD-Cl. The NBD-Hyp is separated and identified by reverse phase HPLC. For the development of the separation of the amino acid derivatives, a coupling to the NBD-CL of a standard containing the hydroxyproline is first carried out. - Hydroxyproline is measured by fluorescence measurement after reverse phase HPLC separation: o Automatic injector o Ultrasep C18 column (30cm * 0.18cm) o 6μm porosity o Fluorescence detector The mobile phase consists of a mixture of acetonitrile / 0.1 mol / l sodium phosphate buffer, pH 7.2 (9:91 v / v), the flow rate is set to 1 ml / min, the elution is carried out in static mode and the cycle is 10 minutes. The mobile phase is filtered beforehand and degassed before use. The solutions are prepared in the following manner: NBD-Cl: 25 mmol dissolved in methanol, OPA = 150 mmol / l dissolved in methanol, phosphate buffer = 0.4 mmol / l, pH adjusted to 7.2. The standard range is prepared from a 50 mg / l hydroxyproline solution. Successive dilutions make it possible to obtain solutions ranging from 0.5 to 40 mg / l. Derivatization and establishment of the calibration curve are performed from 10 .mu.l of a standard solution at different concentrations mixed with 10 .mu.l of the buffer. After addition of 5 μl of OPA and stirring, the tubes are kept for 5 min at ambient temperature and then 10 μl of the NBD-Cl solution are added. The derivate is at 60 ° C in a water bath for 3 minutes, protected from light. The tubes are then removed and the orange color makes it possible to check the derivatization. They are then put in the ice to ensure cooling. 50 μl of this mixture are then injected into the column in order to obtain the calibration curve which must be linear. The samples are treated in the same way.
1.4.4 Etude de l'effet du produit sur la suppression de la MMP-3 (Metalloprotéinase 3) A la fin du temps d'incubation (24 heures), les milieux de culture ont été prélevés, et le dosage de la MMP-3 a été réalisé conformément aux protocoles décrits dans les kits de dosage. Kit de détection de la Métalloprotéinase 3 (MMP-3) : Interchina1.4.4 Study of the effect of the product on the suppression of MMP-3 (Metalloproteinase 3) At the end of the incubation time (24 hours), the culture media were taken, and the MMP-3 assay 3 was performed in accordance with the protocols described in the assay kits. Metalloproteinase 3 Detection Kit (MMP-3): Interchina
2-RESULTATS2-RESULTS
2.1. EVALUATION DE LA CYTOTOXICITE La cytotoxicité a été étudiée par incorporation de la 3H-leucine dans les protéines cellulaires après 24 heures de contact. Les résultats sont regroupés dans le tableau ci-dessous :2.1. EVALUATION OF CYTOTOXICITY Cytotoxicity was studied by incorporation of 3 H-leucine into cellular proteins after 24 hours of contact. The results are summarized in the table below:
2.2 EVALUATION DE LA CROISSANCE CELLULAIRE2.2 EVALUATION OF CELL GROWTH
Croissance cellulaire après 48 heures de contact Les résultats sont regroupés dans le tableau ci-après : l'Cell growth after 48 hours of contact The results are summarized in the table below: the
ns : non significatif Croissance cellulaire après 72 heures de contact Les résultats sont regroupés dans le tableau ci-dessous ns: not significant Cell growth after 72 hours of contact The results are summarized in the table below
ns : non significat f ns: not significant f
Commentaires Les résultats obtenus montrent que le produit ^Complexe de plantes" aux concentrations 0,2%, 0,5%, 1% n'a aucun effet sur l'incorporation de 3H-leucine dans les protéines de fibroblastes humains en culture après 48 et 72 heures de contact avec les cellules. Les résultats révèlent que le produit est dénué de toute activité cytotoxique aux concentrations utilisées.Comments The results obtained show that the product "Plant Complex" at concentrations 0.2%, 0.5%, 1% has no effect on the incorporation of 3 H-leucine in human fibroblast proteins in culture after 48 and 72 hours of contact with the cells The results reveal that the product is devoid of any cytotoxic activity at the concentrations used.
2.3 EVALUTION DE L'ACTIVITE ANTI-INFLAMMATOIRE Dosage de Interleukine 1-α Les résultats sont regroupés dans le tableau ci-après *significativement différent par rapport au témoin positif irradié aux UVB (100 mJ/cm2) (p<0, 01) Dosage de l ' Interleukine 6 Les résultats sont regroupés dans le tableau ci-dessous :2.3 EVALUATION OF ANTI-INFLAMMATORY ACTIVITY Assay of Interleukin 1-α The results are summarized in the table below. * significantly different compared to the positive control irradiated with UVB (100 mJ / cm 2 ) (p <0.01) Determination of Interleukin 6 The results are summarized in the table below:
*significa tivement différent par rapport au témoin posi tif irradié aux UVB (100 mJ/cm2) (p<0, 01) Commentaires Les résultats obtenus montrent que l'irradiation des fibroblastes aux UVB (100 mJ/cm2) augmente significativement la libération de cytokines pro-inflammatoires (IL-Ia et ILβ) dans le milieu de culture respectivement de +68%. Le traitement des cellules par le produit "Complexe de plantes" aux concentrations 0,2 ; 0,5 et 1% préalablement à l'irradiation aux UVB entraine une diminution significative des cytokines pro-inflammatoires. * significantly different from the UVB irradiated positive control (100 mJ / cm 2 ) (p <0.01) Comments The results obtained show that irradiation of fibroblasts with UVB (100 mJ / cm 2 ) significantly increases the release of pro-inflammatory cytokines (IL-Ia and ILβ) in the culture medium respectively by + 68%. Treatment of cells with the product "Plant Complex" at concentrations 0.2; 0.5 and 1% prior to irradiation with UVB leads to a significant decrease in pro-inflammatory cytokines.
2.4. EVALUATION DU TAUX DES PROTEOGLYCANES Dosage des protéoglycanes par incorporation du précurseur radioactif 35SO4 suivi par estimation en FPLC. Protéoglycanes péri-membrannaires Les résultats sont reportés dans le tableau ci-dessous :2.4. EVALUATION OF THE PROTEOGLYCANES RATE Assay of the proteoglycans by incorporation of the radioactive precursor 35 SO 4 followed by estimation by FPLC. Peripheral proteoglycans The results are reported in the table below:
*significativement différent par rapport au témoin p<0,01 (Wilcoxon Rank Sυm Test) * significantly different from the control p <0.01 (Wilcoxon Rank Sυm Test)
Protéoglycanes transmembranaires Les résultats sont reportés dans le tableau ci-après l'l'Transmembrane proteoglycans The results are reported in the table below. the the
*significativement différent par rapport au témoin p<0r01 (Wilcoxon Rank Sum Test) Protéoglycanes matriciels Les résultats sont reportés dans le tableau ci-dessous : * significantly different compared to the control p <0 r 01 (Wilcoxon Rank Sum Test) Matrix proteoglycans The results are reported in the table below:
*significativement différent par rapport au témoin p<0,01 (Wilcoxon Rank Sum Test) Commentaires Les résultats obtenus montrent que le produit "Complexe de plantes" aux concentrations 0,2%, 0,5% et 1%, augmente significativement le taux de protéoglycanes péri-membranaires, transmembranaires et matriciels. * Significantly different from the control p <0.01 (Wilcoxon Rank Sum Test) Comments The results obtained show that the product "Plant Complex" at concentrations 0.2%, 0.5% and 1%, significantly increases the rate of peri-membrane, transmembrane and matrix proteoglycans.
2.5 EVALUATION DU TAUX DES COLLAGENES La séparation et l'identification de hydroxyproline ont été réalisées par HPLC en phase inverse. Les pics de fluorescence, après intégration, ont permis de calculer la concentration de hydroxypoline dans le milieu de culture. Protéoglycanes péri-membranaires Les résultats sont reportés dans le tableau ci-dessous2.5 EVALUATION OF THE COLLAGENES RATE The separation and the identification of hydroxyproline were carried out by reverse phase HPLC. The fluorescence peaks, after integration, made it possible to calculate the concentration of hydroxypoline in the culture medium. Peri-membrane proteoglycans The results are shown in the table below
*significativement différent par rapport au témoin p<0r01 (Wilcoxon Rank Sum Test) Commentaires Les résultat obtenus montrent que le produit "Complexe de plantes" aux concentrations 0,2%, 0,5% et 1%, augmente significativement le taux des collagènes des fibroblastes humains en culture (+21, +38 et +43%) , comparativement à la vitamine C utilisée comme référence positive (+61%) . 2.6 EVALUATION DU TAUX DES MMP3 Le dosage des MMP3 a été réalisé par des kits ELISA au niveau du milieu de culture. Les résultats sont reportés dans le tableau ci-dessous : * Significantly different from control p <0 r 01 (Wilcoxon Rank Sum Test) Comments The results obtained show that the product "Plant Complex" at concentrations 0.2%, 0.5% and 1%, significantly increases the rate human fibroblast collagens in culture (+21, +38 and + 43%), compared with vitamin C used as a positive reference (+ 61%). 2.6 EVALUATION OF THE MMP3 RATE The MMP3 assay was performed by ELISA kits at the level of the culture medium. The results are reported in the table below:
*significativeinent différent par rapport au témoin p<0,01 (Wilcoxon Rank Sum Test) Commentaires Les résultats obtenus montrent que le produit "Complexe de plantes" aux concentrations 0,2%, 0,5% et 1%, diminue l'expression de la métalloprotéinase 3. * Significantly different from the control p <0.01 (Wilcoxon Rank Sum Test) Comments The results obtained show that the product "Plant Complex" at concentrations 0.2%, 0.5% and 1%, decreases the expression of metalloproteinase 3.

Claims

REVENDICATIONS
1. Association d'extraits végétaux à base de Groseille à Maquereau, d'Orchidée Noire et de Tulipe Noire. 1. Association of vegetable extracts made from gooseberry, black orchid and black tulip.
2. Association selon la revendication 1, caractérisée en ce que chacun des extraits végétaux de Groseille à Maquereau, d'Orchidée Noire et de Tulipe Noire, est présent dans une teneur comprise entre 5 et 90%, ces teneurs étant exprimées par rapport au poids total de l'association. 2. Association according to claim 1, characterized in that each of the vegetable extracts of gooseberry, black orchid and black tulip, is present in a content of between 5 and 90%, these contents being expressed relative to the weight total of the association.
3. Association selon la revendication 2, caractérisée en ce que les teneurs en chacun des extraits végétaux sont d'environ 25 à 50% en poids par rapport au poids total de 1 'association. 3. Association according to claim 2, characterized in that the contents of each of the plant extracts are from about 25 to 50% by weight relative to the total weight of the combination.
4. Association selon la revendication 3, caractérisée en ce que les trois extraits végétaux sont présents en quantités sensiblement égales. 4. Association according to claim 3, characterized in that the three plant extracts are present in substantially equal amounts.
5. Composition topique pour le traitement ou la préven¬ tion des dommages de la peau associés au vieillissement de la peau, caractérisée en ce qu'elle comprend une association selon l'une quelconque des revendications 1 à 4. 5. Topical composition for the treatment or prevention of skin damage associated with aging of the skin, characterized in that it comprises an association according to any one of claims 1 to 4.
6. Composition topique selon la revendication 5, caractérisée en ce qu'elle comprend en outre une anti- hyaluronidase telle que Echinacine B, Imperata cylindrica, des protéines de graines d'amarante (Amarantus caudatus) ou des globulines de pois, de l'huile de Calophylum, de l'huile d'Echium, un palmitoyl pentapeptide-3 ou des dérivés tels que le palmitoyl GHK et le palmitoyl GQPR ou le palmitoyl VGVAPG associé à un céramide-2, ainsi qu'un céramide. 6. topical composition according to claim 5, characterized in that it further comprises an anti-hyaluronidase such as Echinacin B, Imperata cylindrica, amaranth seed protein (Amarantus caudatus) or pea globulins, Calophylum oil, Echium oil, palmitoyl pentapeptide-3 or derivatives such as palmitoyl GHK and palmitoyl GQPR or palmitoyl VGVAPG combined with a ceramide-2, and a ceramide.
7. Utilisation d'une association selon l'une quelconque des revendications 1 à 4, pour la préparation d'une compo¬ sition topique destinée à lutter contre les dommages de la peau associés au vieillissement de la peau. 7. Use of an association according to any one of claims 1 to 4, for the preparation of a topical composition for combating skin damage associated with aging of the skin.
8. Procédé cosmétique pour combattre les dommages de la peau associés au vieillissement de la peau, qui comprend une étape consistant à appliquer à des zones de la peau affectées une composition contenant une quantité efficace de la composition topique selon l'une quelconque des revendications 5 ou 6. 8. Cosmetic method for combating skin damage associated with aging of the skin, which comprises a step of applying to areas of the skin affected a composition containing an effective amount of the topical composition according to any of claims 5 or 6.
9. Procédé cosmétique pour l'amélioration de l'aspect externe, caractérisé en ce qu'il comprend une étape consistant à appliquer une composition topique selon l'une quelconque des revendications 5 ou 6. 9. Cosmetic process for improving the external appearance, characterized in that it comprises a step of applying a topical composition according to any one of claims 5 or 6.
EP05775497A 2004-06-03 2005-06-01 Association of vegetal extracts based on gooseberries, black orchids and black tulips and topical composition comprising the association of said vegetal extracts Withdrawn EP1830787A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0406003A FR2871058B1 (en) 2004-06-03 2004-06-03 ASSOCIATION BASED ON PLANT EXTRACTS AND TOPICAL COMPOSITION CONTAINING THE SAME
PCT/FR2005/001346 WO2006000689A1 (en) 2004-06-03 2005-06-01 Association of vegetal extracts based on gooseberries, black orchids and black tulips and topical composition comprising the association of said vegetal extracts

Publications (1)

Publication Number Publication Date
EP1830787A1 true EP1830787A1 (en) 2007-09-12

Family

ID=34948698

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05775497A Withdrawn EP1830787A1 (en) 2004-06-03 2005-06-01 Association of vegetal extracts based on gooseberries, black orchids and black tulips and topical composition comprising the association of said vegetal extracts

Country Status (5)

Country Link
US (1) US20080020077A1 (en)
EP (1) EP1830787A1 (en)
CA (1) CA2566905A1 (en)
FR (1) FR2871058B1 (en)
WO (1) WO2006000689A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20055644A0 (en) 2005-12-02 2005-12-02 Nokia Corp group Communications
FR2928090B1 (en) * 2008-03-03 2014-10-10 Lvmh Rech USE OF AN EXTRACT OF ORCHID VANDA COERULEA AS A MOISTURIZING AGENT FOR THE SKIN
FR2928549B1 (en) * 2008-03-13 2013-07-26 Lvmh Rech USE OF AN EXTRACT OF BRASSOCATTLEYA MARCELLA KOSS ORCHIDEE AS AN AGENT TO PREVENT OR DELAY THE APPEARANCE OF SIGNS OF SKIN AGING
CN102099049B (en) * 2008-05-30 2015-05-27 戴纳米斯制药公司 Natrual inhibitor of the enzymatic production of 3-deoxy-glucosone
FR2937533B1 (en) * 2008-10-29 2010-11-26 Oreal ASSOCIATION OF ORCHID EXTRACT AND SOY PROTEIN EXTRACT
KR20160091037A (en) * 2015-01-23 2016-08-02 (주)아모레퍼시픽 Composition comprising gooseberry or glutathione
CN107267289A (en) * 2017-07-14 2017-10-20 新疆郁金香生物科技有限公司 A kind of extracting method of root tuber of aromatic turmeric essential oil
FR3068893B1 (en) * 2017-07-17 2021-02-19 Caster TULIP EXTRACT
CN108272727A (en) * 2018-04-08 2018-07-13 上海粉蝶化妆品有限公司 A kind of rain lily meat lip orchid face cream
US20220142910A1 (en) * 2020-11-06 2022-05-12 Dianne Martin Bastian Composition including all natural botanical peptide ingredients for topical skin applications

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02279618A (en) * 1989-04-20 1990-11-15 Ichimaru Pharcos Co Ltd Cosmetic containing extract of plant of family orchidaceae
FR2699818B1 (en) * 1992-12-24 1995-02-03 Oreal Cosmetic or pharmaceutical composition containing in combination a polyphenol and an extract of gingko.
JP3805022B2 (en) * 1996-06-20 2006-08-02 株式会社ノエビア Topical skin preparation
DE69943187D1 (en) * 1999-08-26 2011-03-24 Jean Julia COSMETIC COMPOSITION CONTAINING OILS FROM CYNARA CARDUNCULUS OR SILYBUM MARIANUM
FR2804864B1 (en) * 2000-02-11 2003-04-04 Serobiologiques Lab Sa EXTRACTS OF RESIDUES FROM THE MANUFACTURE OF WINE AND THEIR USE IN COSMETICS OR PHARMACOLOGY
EP1370272A1 (en) * 2001-03-02 2003-12-17 Biopharmacopae Design International Inc. Inhibitors of extracellular proteases
WO2002069921A1 (en) * 2001-03-07 2002-09-12 Unilever Plc Hair colouring compositions
JP2003040758A (en) * 2001-07-25 2003-02-13 Matsukawa Kagaku:Kk Cosmetic
US20040133956P1 (en) * 2003-01-03 2004-07-08 Jury Mark C. Magnolia plant named 'JURmag1'
JP2004269430A (en) * 2003-03-10 2004-09-30 Ichimaru Pharcos Co Ltd Composition for hair treatment and hair cosmetic for damaged hair

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006000689A1 *

Also Published As

Publication number Publication date
WO2006000689A1 (en) 2006-01-05
FR2871058A1 (en) 2005-12-09
US20080020077A1 (en) 2008-01-24
FR2871058B1 (en) 2006-09-22
CA2566905A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
EP1830787A1 (en) Association of vegetal extracts based on gooseberries, black orchids and black tulips and topical composition comprising the association of said vegetal extracts
FR2975495A1 (en) METHOD OF SCREENING ACTIVE INGREDIENTS PROMOTING AGES DEGLYCATION
EP2691074A1 (en) Composition based on camellia japonica and polygonum hydropiper for protecting the skin
EP2046281B1 (en) Use of a mimosa seed extract (acacia dealbta, acacia farnesiana ou acacia decurrens) in a cosmetic composition
EP3980124B1 (en) Extract of moringa peregrina seed cake, method for obtaining same and use thereof in cosmetic or nutricosmetic compositions
WO2015049268A1 (en) Use of an oily composition containing an extract of daylily in order to improve the firmness of the skin
FR2948877A1 (en) Topical composition, useful e.g. to protect and regenerate the skin, comprises an active complex comprising combination of plant extracts containing Alaria esculenta algae extract and Crambe maritima extract
EP2046356B1 (en) Use of an extract of gleditsia in cosmetics and in dermatology
EP2699227B1 (en) Plant extract complex for skin protection
FR3030273A1 (en) COMPOSITION COMPRISING LOTUS EXTRACT, HAMAMELIS EXTRACT AND ZINC, AND COSMETIC USE THEREOF
EP2811977B1 (en) Use of an apple tree leaf extract in a cosmetic skin-firming composition
EP2811978B1 (en) Use of an apple tree bark extract in a cosmetic anti-ageing composition
FR2859102A1 (en) USE OF A RHODIOLA CRENULATA EXTRACT BY TOPIC
FR2885052A1 (en) Use of a maca extract (Lepidium meyenii) for the preparation a dermatological medicament for topical use to prevent and treat the deficiency of cutaneous microcirculation
EP3229923B1 (en) Cosmetic use of an extract of eschscholtzia californica
FR2997854A1 (en) Use of Saba senegalensis extract for performing anti-aging action on skin and its annexes or mucous membranes, preferably e.g. preventing, delaying and/or limiting the signs of endogenous or exogenous skin aging
FR3021539A1 (en) COSMETIC AND / OR DERMATOLOGICAL COMPOSITION COMPRISING A VEGETABLE EXTRACT AND A GENE ACTIVATOR
FR3110346A1 (en) Extract of Moringa peregrina seed cake, process for obtaining it and its use in cosmetic or nutricosmetic compositions
WO2014001465A2 (en) Soothing topical composition containing paeonia and nymphaea extracts
FR2984740A1 (en) Use of Ravenala extract for antiaging action and protecting and regenerating skin, mucous membranes or its annexes, where the antiaging action is a preventive, delay and/or limitation action of signs of endogenous or exogenous skin aging
WO2012172200A1 (en) Composition based on samanea saman for protecting the skin
FR2885049A1 (en) Topical cosmetic and/or dermatological composition, useful to protect the skin and to fight against the climatic and environmental effect, comprises a seed extract of Araucaria
FR2997855A1 (en) Use of Saba senegalensis extract for softening skin such as normal skin, dehydrated skin and defatted skin or mucous membranes, unifying color and/or tone of skin and stimulating angiogenesis in skin
FR2973698A1 (en) GLEDITSIA - BASED COMPOSITION FOR TREATING ADDITIONAL OVERLOADS.
EP2849720A2 (en) Use of a chaste tree extract for preparing a cosmetic and/or dermatological composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1108649

Country of ref document: HK

17Q First examination report despatched

Effective date: 20080505

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MESYL LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081118

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1108649

Country of ref document: HK